Neri Serneri G G, Gensini G F, Poggesi L, Trotta F, Modesti P A, Boddi M, Ieri A, Margheri M, Casolo G C, Bini M
Clinica Medica I, University of Florence, Italy.
Lancet. 1990 Mar 17;335(8690):615-8. doi: 10.1016/0140-6736(90)90407-v.
399 out of 474 inpatients with unstable angina were monitored for 48 h and 97 of these were found to be refractory to conventional antianginal treatments and entered a randomised double-blind study. With the initial protocol heparin infusion or bolus were compared with aspirin; with a modified protocol, heparin infusion, the best of these three treatments, was compared with alteplase. Patients were monitored for 3 days after starting treatment and then observed clinically for 4 more days. On the first days of treatment heparin infusion significantly decreased the frequency of angina (by 84-94%), episodes of silent ischaemia (by 71-77%), and the overall duration of ischaemia (by 81-86%). Heparin bolus and aspirin were not effective. Alteplase caused small (non-significant) reductions on the first day only. Only minor bleeding complications occurred.
474例不稳定型心绞痛住院患者中的399例接受了48小时的监测,其中97例被发现对传统抗心绞痛治疗无效,进入了一项随机双盲研究。按照初始方案,将肝素输注或推注与阿司匹林进行比较;按照改良方案,将肝素输注(这三种治疗方法中效果最佳的)与阿替普酶进行比较。患者在开始治疗后接受3天的监测,然后再进行4天的临床观察。在治疗的第一天,肝素输注显著降低了心绞痛发作频率(降低84%-94%)、无症状性缺血发作次数(降低71%-77%)以及缺血总时长(降低81%-86%)。肝素推注和阿司匹林无效。阿替普酶仅在第一天引起了轻微(无统计学意义)的降低。仅发生了轻微的出血并发症。